Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2005



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Basic Aspects of Tumor Immunology II (C3)


Organizer(s) Nicholas P. Restifo and Nina Bhardwaj
March 19—24, 2005
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Nov 18, 2004
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 19, 2005

Supported by The Director's Fund

Summary of Meeting:
The identification of a large number of tumor-associated antigens has opened up a world of possibilities for cancer immunologists. We have devised immunization strategies that enable us to boost immune responses against these antigens -- some encouraging but preliminary results have been obtained in the clinic. Most importantly, the adoptive transfer of tumor-specific T cells has emerged as an immunotherapeutic strategy that can cause solid tumors to reliably shrink. The challenge now is to gain a deeper understanding of how immune cells traffic to, interact with, and potentially destroy tumor cells. This meeting will bring together experts from academia and industry in an effort to elucidate the basic immunology that could make it possible to trigger and sustain an immune response capable of mediating the complete destruction of tumor cells.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SATURDAY, MARCH 19

15:00—19:00
Registration

Longs Foyer
18:00—19:00
Refreshments

Longs Foyer
19:00—21:00
Opening Addresses
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
Rafi Ahmed, Emory University School of Medicine, USA
Memory CD8 T Cell Differentiation during Acute Versus Chronic Viral Infection

Craig B. Thompson, Memorial Sloan Kettering Cancer Center, USA
Fueling an Anti-Tumor Response


SUNDAY, MARCH 20

07:00—08:00
Breakfast

Grays/Longs
08:00—09:00
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
Steven A. Rosenberg, NCI, National Institutes of Health, USA
Human Cancer Immunotherapy

09:00—09:20
Coffee Break

Longs Foyer
09:20—11:00
Novel Cellular Immunotherapies
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
Richard J. O'Reilly, Memorial Sloan-Kettering Cancer Center, USA
Adoptive Transfer of Donor-Derived Antigen0Specific T cells for the Treatment of Hematologic Malignancies Following Allogeneic Hematopoietic Cell Transplants

* Gary J. Nabel, Sanofi, USA
Building Better Cancer Vaccines: Lessons from HIV

Philip D. Greenberg, University of Washington, USA
Cellular and Molecular Engineering of T Cell Responses to Promote Eradication of Tumors

11:00—13:00
Poster Setup

Grays/Longs
13:00—22:00
Poster Viewing

Grays/Longs
14:00—16:30
Afternoon Session 1A: Novel Clinical Approaches

Shavano
Jeffrey Weber, New York University, USA
Novel Adjuvants Approaches for Melanoma Vaccines

A. Karolina Palucka, Tha Jackson Laboratory for Genomic Medicine, USA
Dendritic Cell Vaccines in Cancer

Thomas Gajewski, University of Chicago, USA
Understanding and Modifying the Melanoma Tumor Microenvironment

Craig L. Slingluff, University of Virginia, USA
Multipeptide Vaccines for Melanoma - Targeting CD8 and CD4 Cells

Lisa H. Butterfield, University of Pittsburgh, USA
AFP Specific T cell Responses in HCC

Victor Appay, INSERM and Kumamoto University, France
The Physiological Role of Cytotoxic CD4(+) T-Cells: The Holy Grail?

Adam J. Adler, University of Connecticut Health Center, USA
In vivo Cyclophosphamide and IL-2 Treatment Impedes Self-Antigen-Induced Effector CD4 Cell Tolerization: Implications for Adoptive Immunotherapy

14:00—16:30
Afternoon Session 1B: New Findings in the Mouse

Torreys
Bruce W. Robinson, University of Western Australia, Australia
The Biological Significance of Cross-Presentation to Tumor Immunology

Federica Cavallo, University of Turin, Italy
Induction of a Long-Term Anti-Tumor Immune Memory in Her-2 Transgenic Mice

Ofir Goldberger, Fluidigm Corporation, USA
T Cell Precursor Frequency Alone is Insufficient to Trigger Tumor Regression

Catherine Sautes-Fridman, Cordeliers Research Center, INSERM U872, France
The Role of FcgR in Tumor Immunity and Tumor Escape

* Frédéric Lévy, Ludwig Institute for Cancer Research, Switzerland
Immunoproteasome Limits the Induction of Anti-Melan-A T Cell Response in vivo

Eli Young, Genitrix, LLC, USA
Opsonokines: Breaking the Immunogenicity Barrier

Wilfred A. Jefferies, University of British Columbia, Canada
The Restoration TAP Expression in Carcinomas Increases Tumor Specific Immune Responses and Survival

16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—19:00
New Strategies for Cancer Immunotherapy I
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
* Cliona M. Rooney, Baylor College of Medicine, USA
Improving Survival, Expansion And Persistence Of Adoptively-Transferred Tumor-Specific CTLs.

Carl H. June, University of Pennsylvania, USA
Rebuilding Immunity after Chrmotherapy

Ronald Levy, Stanford University, USA
Current Immunotherapies for Hematologic Malignancies

19:00—20:00
Social Hour

Grays/Longs
19:30—22:00
Poster Session 1

Grays/Longs

MONDAY, MARCH 21

07:00—08:00
Breakfast

Grays/Longs
08:00—09:00
New Strategies for Cancer Immunotherapy II
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
Nicholas P. Restifo, NCI, National Institutes of Health, USA
Translating New Basic Immunology into Human Immunotherapies

09:00—09:20
Coffee Break

Longs Foyer
09:20—11:00
Innate Immunity and Autoimmunity
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
Caetano Reis e Sousa, Francis Crick Institute, UK
Learning from Viruses: How to Activate Dendritic Cells for Anti-Tumour Immunity

* Pamela S. Ohashi, Princess Margaret Cancer Centre, Canada
Manipulating Tolerance and Immune Surveillance

Alexandre Corthay, University of Oslo and Rikshospitalet University Hospital, Norway
Primary Antitumor Immune Response Mediated by CD4+ T Cells

11:00—12:00
Poster Setup

Grays/Longs
11:00—12:00
Lunch

Grays/Longs
11:30—14:00
Poster Session 2

Grays/Longs
14:00—16:30
Afternoon Session 2A: Toll-Like Receptors/ Death, Danger and Dendritic Cells

Shavano
* Arthur M. Krieg, Checkmate Pharmaceuticals, USA
Activating Innate and Adaptive Immunity by in vivo Activation of TLR9 with CpG Oligos

Charles Drake, Johns Hopkins University, USA
CD4+ T Cell Tolerance to Protstate Cancer

Vincenzo Cerundolo, University of Oxford, UK
The Role of NKT Cells in Assisting Priming of Antigen Specific T Cells

Jonathan P. Schneck, Johns Hopkins School of Medicine, USA
Develpment of Artificial Antigen Presenting Complexes, a APC, for Adaptive Immunotherapy

Matteo Bellone, Universita Vita - Salute San Raffaele, Italy
Peripheral T Cell Tolerance Occurs Early during Prostate Cancer Development and Can be Rescued by Dendritic Cell Immunization

Bertrand Huard, Centre Medical Universitaire, Switzerland
Cross-Presentation of a B16 Neo-Antigen Induces the Accumulation of Anergic CD8+ T Cells

Lloyd M. Stoolman, University of Michigan, USA
Vascular Adhesive Interactions Control Clinical Responses during Adoptive Immunotherapy of Murine Cancer

14:00—15:25
Afternoon Session 2B: Editor's Roundtable

Torreys
* Alison Farrell, Nature Publishing Group, USA

* Stephen James Simpson, Arthritis Research UK, UK

Peter T. Lee, Immunity, Cell Press, USA

Ushma Savla Neill, Journal of Clinical Investigation & Molecular Metabolism, USA

15:30—16:30
Afternoon Session 2B: Altered States: T Cells in Immunotherapy

Torreys
* Daniel E. Speiser, Ludwig Center, University of Lausanne, Switzerland
Distinguishing Protective from Non-Protective T Cell Responses

Nathalie Rufer, Swiss Institute for Experimental Cancer Research, Switzerland
Ex vivo Tracking of Dominant Monoclonal T-Cell Responses

Bernard A. Fox, Earle A Chiles Research Institute, USA
The Uses and Mechanisms of Lymphodepletion

16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—19:00
Dendritic Cells
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
* Nina Bhardwaj, Ichan School of Medicine at Mt Sinai, USA
Crosspresentation of Cell Associated Antigens by Dendritic Cells

Yong-Jun Liu, Sanofi, USA
TSLP and IL7

Michael L. Dustin, University of Oxford, UK
The immunological synapse

Alex Y.C. Huang, Case Western Reserve University School of Medicine, USA
Short Talk: Imaging Immune Cell Function in situ


TUESDAY, MARCH 22

07:00—08:00
Breakfast

Grays/Longs
08:00—09:00
Autoimmunity
Meeting has ended...abstracts no longer viewable online.

* Jeffrey A. Bluestone, University of California, San Francisco, USA
Autoimmunity and Cancer Immunity: A Balancing Act

09:20—11:00
Maintenance of the Anti-Tumor Immune Response
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
Leo Lefrançois, University of Connecticut Health Center, USA
Regulation of DC8+ T Cell Memory Lineage Development

Lieping Chen, Yale University, USA
B7-H1 in Cancer Immune Evasion

* Patrick Hwu, University of Texas MD Anderson Cancer Center, USA
The Use of Dendritic Cells to Enhance the Effectiveness of Adoptively Transferred T-Cells

Samuel C. Silverstein, Columbia University College of Physicians & Surgeons, USA

09:20—09:40
Coffee Break

Longs Foyer
11:00—13:00
Poster Setup

Grays/Longs
13:00—22:00
Poster Viewing

Grays/Longs
14:00—15:00
Afternoon Session 3: Special Lecture

Shavano
Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Genetic Mechanism of Dominant Tolerance

15:00—16:30
Afternoon Session 3: T Regulatory Cells

Shavano
* Ciriaco A. Piccirillo, McGill University, Canada
Control of Immune Responses by Naturally-Occurring CD4+CD25+ Regulatory Lymphocytes: Lessons from in vitro and in vivo Models

* Rienk Offringa, Genentech Inc., USA
Analysis of CD4 T Cell Immunity Against HPV16 in Patients with Cervical Neoplasia and Healthy Subjects

Awen M. Gallimore, University of Wales College of Medicine, UK
The Effect of CD4+CD25+ Regulatory T Cells on Anti-Tumor Immune Responses in Mice and Men

Johannes W. Vieweg, University of Florida, USA
Disruption of Regulatory Pathways to Enhance the Efficacy of Cancer Vaccines

Weiping Zou, University of Michigan, USA
Regulatory T Cells and Preliminary Results in a Clinical Trial with Ontak Treated Cancer Patients

16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—19:00
T Regulatory Cells
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
* Abul K. Abbas, University of California, San Francisco, USA
The Control of T-Cell Activation vs Tolerance

Shimon Sakaguchi, Osaka University, Japan
Control of Immune Response by Foxp3+ CD25+ CD4 Tr Cells

Harald von Boehmer, Harvard Medical School, USA
Dynamics of Suppressor T Cells: in vivo veritas

Rong-Fu Wang, Baylor College of Medicine, USA
Short Talk: Regulatory T Cells in Prostate Cancer

19:00—20:00
Social Hour

Grays/Longs
19:30—22:00
Poster Session 3

Grays/Longs

WEDNESDAY, MARCH 23

07:00—08:00
Breakfast

Grays/Longs
08:00—09:00
Concluding Address
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
Richard A. Flavell, HHMI/Yale University School of Medicine, USA
Potential Molecular and Cellular Components of a Productive Anti-Tumor Immune Response: A Summing Up

09:00—09:20
Coffee Break

Longs Foyer
09:20—11:00
Bench-to-Bedside and Back Again
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
New Strategies for Cancer Immunotherapy

Pedro Romero, Ludwig Institute for Cancer Research, Switzerland
Molecularly Defined Melanoma Vaccines

* Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
Allogenric Marrow Translantation Immunotherapy for Hematologic Malignacies

14:00—15:00
Afternoon Session 4A: Special Lecture

Shavano
Lorenzo Moretta, University of Genova, Italy
Human NK Cells: Their Receptors and Functional Interactions

15:00—16:30
Afternoon Session 4A: Tumor Destruction vs. Tumor Escape

Shavano
Yang-Xin Fu, utsouthwestern medical center, USA
Changing the Battlefield: Altering Immune Responses inside Tumor

* Richard G. Vile, Mayo Clinic, USA
Inducing Autoimmune T Cell Responses to Treat Melanoma

Michael Caligiuri, Ohio State University, USA
IL-15

Barbara Seliger, Martin Luther University, Germany
Molecular Mechanisms of the Deficient MHC Class I Antigen Processing in Tumors

14:00—16:30
Afternoon Session 4B: Novel Reagents

Torreys
* Olivera J. Finn, University of Pittsburgh School of Medicine, USA
Tumor Antigen MUC1-Based Reagents for Gene Therapy and Immunotherapy of Cancer

Zelig Eshhar, Weizmann Institute of Science, Israel
Adoptive Cellular Immunotherapy of Prostate and Breast Cancer Using T-Bodies

Suzanne Ostrand-Rosenberg, University of Maryland, USA
Reversal of Tumor-Induced Immune Suppression: Complex Interplay between Activated T Cells and M1 Macrophages

Dapeng Zhou, MD Anderson Cancer Center, USA
The Identity of a Natural NKT Cell Ligand: Implications for Cancer Immunotherapy

Juergen Kuball, University of Mainz, Germany
Redirection of the Specificity of Human Tumor-Reactive CD4(+) and CD8(+) T Cells with a High-Affinity TCR

Fred J. Ramsdell, Parker Institute for Cancer Immunotherapy, USA
Mechanisms of IL-21-Mediated Tumor Rejection

* Jay A. Berzofsky, NCI, National Institutes of Health, USA
Mechanism of Protection Against Breast Cancers in HER-2/neu Transgenic Mice by HER-2/neu Adenoviral Vaccine

16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—19:00
Cytokines and Chemokines
Meeting has ended...abstracts no longer viewable online.

Shavano/Torreys
Charles D. Surh, La Jolla Institute for Allergy and Immunology, USA
Key Cytokines in Lymphocyte Homeostasis

Warren J. Leonard, National Institutes of Health, USA
IL-21

* Crystal L. Mackall, Stanford University, USA
Incorporating IL-7 into Immunotherapy for Cancer

19:00—20:00
Social Hour

Grays/Longs
20:00—23:00
Entertainment

Grays/Longs

THURSDAY, MARCH 24

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

3M Pharmaceuticals Xcyte Therapies, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676